Industry

MADISON, Wis.–(BUSINESS WIRE)–Navitus, the nation’s first and largest transparent, pass-through pharmacy benefit manager (PBM), today announced the expanded implementation of Banjo Health. Banjo is an advanced automation platform with artificial intelligence (AI) capabilities designed to modernize and simplify prior authorization workflows that are central to pharmacy benefits management. Now implemented across employer and health plan … [Read more…]

Retailer and Market Demands Drive Rapid Traceability Adoption SALT LAKE CITY–(BUSINESS WIRE)–ReposiTrak (NYSE: TRAK), the industry leader in food traceability and regulatory compliance, announced that the push for traceability is now being driven by market forces rather than federal timelines. During a recent MorningNewsBeat interview, ReposiTrak Chairman and CEO Randy Fields and Affiliated Foods, Inc., … [Read more…]

TAIPEI, Taiwan–(BUSINESS WIRE)–Taiwan has achieved the World Health Organization’s (WHO) goal of eliminating Hepatitis C by 2025, reaching this milestone ahead of the global timeline. Through cross-sectoral collaboration from central to local levels, the nation has established an integrated strategy covering prevention, screening, and treatment. The results have been outstanding, with all key indicators surpassing … [Read more…]

Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy of Dermatology and Venereology, highlight nemolizumab’s fast onset of action and improvement of itch and sleep disturbance in patients with moderate-to-severe atopic dermatitis and prurigo nodularis1 Significant improvements in itch were observed as early as … [Read more…]

Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based on SWIFT trials showing significantly lower rate of annualized asthma exacerbations in patients receiving depemokimab versus placebo SWIFT data included reduction in exacerbations requiring hospitalization and/or emergency department visits with depemokimab An … [Read more…]

New publication demonstrates that insitro’s POSH platform — integrating pooled CRISPR screening and self-supervised deep learning — successfully breaks the historic compromise between scale and depth to more rapidly identify novel therapeutic targets SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–insitro, the AI therapeutics company built on causal biology, today announced the publication of research in Nature Communications … [Read more…]

MIAMI–(BUSINESS WIRE)–Cardone Ventures, backed by billionaire investor, Grant Cardone and his business partners Brandon and Natalie Dawson, today announced that it has submitted an unsolicited, non-binding proposal to acquire PetMed Express, Inc. (Nasdaq: PETS) (“PetMeds”) for $4.25 per share in cash, representing an implied equity value of approximately $89 million. The proposal was delivered to … [Read more…]

ARLINGTON, Va.–(BUSINESS WIRE)–Recognizing that research facilities use five to 10 times as much energy as office buildings, the International Institute for Sustainable Laboratories (I2SL) has launched the first laboratory-specific software service for creating automated energy audits. The Actionable Insights and Measures (AIM) software allows lab owners, facility managers, engineers, and consultants around the world to … [Read more…]

BOSTON & SHANGHAI–(BUSINESS WIRE)–Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that the first patient has been enrolled in MOSAIC, the company’s Phase 2a clinical trial evaluating ECC4703, ECC0509 and their combination in adults with MRI-based or clinically defined metabolic dysfunction-associated steatohepatitis (MASH). The … [Read more…]

LONDON & SAN FRANCISCO–(BUSINESS WIRE)–Today, Latent Labs announces Latent-X2, a frontier AI model that can design drug-like biologics without iteration. Drug hunters can use Latent Lab’s AI platform, built on Latent-X2, to access difficult targets and accelerate development timelines by reducing wet lab work. The generated designs display drug-like properties including low ex vivo immunogenicity, … [Read more…]